Actinium Pharmaceuticals, Inc.

Actinium is developing two radioimmunotherapy (RIT) drugs based on its APIT drug delivery platform. Iomab-B is being developed for bone marrow conditioning for hematopoietic stem cell transplantation (HSCT) in relapsed and refractory AML patients age of 55 or older. The company is currently preparing for Phase III trial with Iomab-B. Its other product is Actimab-A, an antibody-drug construct containing iodine-131 used in myeloconditioning for HSCT in various indications.

More Client Stories

CEO, Usio, Inc.

Louis Hoch
CEO, Sonoma Pharmaceuticals

Jim Schutz
Former CEO, IsoRay

Dwight Babcock

We help you market your investment story with maximum impact and deliver your corporate message effectively

Contact Us
or call
+1 954 360 9998